Any feedback?
Literature summary for 3.4.11.18 extracted from
- The anti-angiogenic agent fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase (1998), Proc. Natl. Acad. Sci. USA, 95, 12153-12157.
Application
| Application | Comment | Organism |
|---|---|---|
| medicine | the modification of the active site residue His79 by the inhibitors fumagillin and ovalicin may prevent the action of the enzyme on proteins or peptides involved in angiogenesis. These compounds may be effective pharmacological agents against pathogenic and resistant forms of Escherichia coli and other microorganisms | Escherichia coli |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| fumagillin | fumagillin covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase | Escherichia coli |  |
| ovalicin | covalently modifies a conserved active-site histidine in the Escherichia coli methionine aminopeptidase | Escherichia coli | |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Escherichia coli | - |
- |
- |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
